Standard BioTools Inc. (NASDAQ: LAB) Stock Competitors & Peer Comparison
See LAB's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Equipment & Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for LAB and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LAB | $0.80 | -0.01% | 313.2M | -11.43 | -$0.07 | N/A |
| SIRO | $109.97 | +0.00% | 22B | 31.88 | $3.45 | N/A |
| HIMS | $31.59 | +6.51% | 7B | -315.90 | -$0.10 | N/A |
| MMED | $19.60 | +6.41% | 5.5B | -25.29 | -$0.78 | N/A |
| OMCL | $36.81 | +1.80% | 1.7B | 19.27 | $1.91 | N/A |
| DRTS | $13.14 | +1.15% | 1.2B | -19.61 | -$0.67 | N/A |
| MLAB | $102.65 | +1.62% | 574.4M | 10.36 | $9.91 | +0.62% |
| STXS | $1.42 | +4.41% | 139M | -8.35 | -$0.17 | N/A |
| FONR | $19.09 | +0.00% | 117.8M | 19.09 | $1.00 | N/A |
| LNSR | $6.04 | +5.32% | 74.2M | 6.16 | $0.98 | N/A |
Stock Comparison
Sirona Dental Systems, Inc. (NASDAQ: SIRO)
LAB vs SIRO Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, SIRO has a market cap of 22B. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while SIRO trades at $109.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas SIRO's P/E ratio is 31.88. In terms of profitability, LAB's ROE is -0.18%, compared to SIRO's ROE of +0.14%. Regarding short-term risk, LAB is more volatile compared to SIRO. This indicates higher risk in terms of short-term price fluctuations for LAB.Check SIRO's competition here
Hims & Hers Health, Inc. (NYSE: HIMS)
LAB vs HIMS Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, HIMS has a market cap of 7B. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while HIMS trades at $31.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas HIMS's P/E ratio is -315.90. In terms of profitability, LAB's ROE is -0.18%, compared to HIMS's ROE of -0.02%. Regarding short-term risk, LAB is less volatile compared to HIMS. This indicates lower risk in terms of short-term price fluctuations for LAB.Check HIMS's competition here
MiniMed Group, Inc. Common Stock (NASDAQ: MMED)
LAB vs MMED Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, MMED has a market cap of 5.5B. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while MMED trades at $19.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas MMED's P/E ratio is -25.29. In terms of profitability, LAB's ROE is -0.18%, compared to MMED's ROE of -0.14%. Regarding short-term risk, LAB is less volatile compared to MMED. This indicates lower risk in terms of short-term price fluctuations for LAB.Check MMED's competition here
Omnicell, Inc. (NASDAQ: OMCL)
LAB vs OMCL Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, OMCL has a market cap of 1.7B. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while OMCL trades at $36.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas OMCL's P/E ratio is 19.27. In terms of profitability, LAB's ROE is -0.18%, compared to OMCL's ROE of +0.03%. Regarding short-term risk, LAB is more volatile compared to OMCL. This indicates higher risk in terms of short-term price fluctuations for LAB.Check OMCL's competition here
Alpha Tau Medical Ltd (NASDAQ: DRTS)
LAB vs DRTS Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, DRTS has a market cap of 1.2B. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while DRTS trades at $13.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas DRTS's P/E ratio is -19.61. In terms of profitability, LAB's ROE is -0.18%, compared to DRTS's ROE of -0.73%. Regarding short-term risk, LAB is more volatile compared to DRTS. This indicates higher risk in terms of short-term price fluctuations for LAB.Check DRTS's competition here
Mesa Laboratories, Inc. (NASDAQ: MLAB)
LAB vs MLAB Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, MLAB has a market cap of 574.4M. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while MLAB trades at $102.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas MLAB's P/E ratio is 10.36. In terms of profitability, LAB's ROE is -0.18%, compared to MLAB's ROE of +0.04%. Regarding short-term risk, LAB is more volatile compared to MLAB. This indicates higher risk in terms of short-term price fluctuations for LAB.Check MLAB's competition here
Stereotaxis, Inc. (AMEX: STXS)
LAB vs STXS Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, STXS has a market cap of 139M. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while STXS trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas STXS's P/E ratio is -8.35. In terms of profitability, LAB's ROE is -0.18%, compared to STXS's ROE of -1.53%. Regarding short-term risk, LAB is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for LAB.Check STXS's competition here
Fonar Corp. (NASDAQ: FONR)
LAB vs FONR Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, FONR has a market cap of 117.8M. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while FONR trades at $19.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas FONR's P/E ratio is 19.09. In terms of profitability, LAB's ROE is -0.18%, compared to FONR's ROE of +0.04%. Regarding short-term risk, LAB is more volatile compared to FONR. This indicates higher risk in terms of short-term price fluctuations for LAB.Check FONR's competition here
LENSAR Inc (NASDAQ: LNSR)
LAB vs LNSR Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, LNSR has a market cap of 74.2M. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while LNSR trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas LNSR's P/E ratio is 6.16. In terms of profitability, LAB's ROE is -0.18%, compared to LNSR's ROE of -5.15%. Regarding short-term risk, LAB is less volatile compared to LNSR. This indicates lower risk in terms of short-term price fluctuations for LAB.Check LNSR's competition here
Kindly MD, Inc. (NASDAQ: KDLY)
LAB vs KDLY Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, KDLY has a market cap of 68.1M. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while KDLY trades at $11.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas KDLY's P/E ratio is -15.48. In terms of profitability, LAB's ROE is -0.18%, compared to KDLY's ROE of -0.85%. Regarding short-term risk, LAB is more volatile compared to KDLY. This indicates higher risk in terms of short-term price fluctuations for LAB.Check KDLY's competition here
NeueHealth, Inc. (NYSE: NEUE)
LAB vs NEUE Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, NEUE has a market cap of 60.9M. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while NEUE trades at $6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas NEUE's P/E ratio is -0.38. In terms of profitability, LAB's ROE is -0.18%, compared to NEUE's ROE of +0.05%. Regarding short-term risk, LAB is more volatile compared to NEUE. This indicates higher risk in terms of short-term price fluctuations for LAB.Check NEUE's competition here
SANUWAVE Health Inc. (NASDAQ: SNWV)
LAB vs SNWV Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, SNWV has a market cap of 50.6M. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while SNWV trades at $5.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas SNWV's P/E ratio is 17.82. In terms of profitability, LAB's ROE is -0.18%, compared to SNWV's ROE of +17.28%. Regarding short-term risk, LAB is less volatile compared to SNWV. This indicates lower risk in terms of short-term price fluctuations for LAB.Check SNWV's competition here
Ekso Bionics Holdings, Inc. (NASDAQ: EKSO)
LAB vs EKSO Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, EKSO has a market cap of 38.6M. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while EKSO trades at $15.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas EKSO's P/E ratio is -3.11. In terms of profitability, LAB's ROE is -0.18%, compared to EKSO's ROE of -1.77%. Regarding short-term risk, LAB is less volatile compared to EKSO. This indicates lower risk in terms of short-term price fluctuations for LAB.Check EKSO's competition here
HeartBeam, Inc. (NASDAQ: BEAT)
LAB vs BEAT Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, BEAT has a market cap of 29.1M. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while BEAT trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas BEAT's P/E ratio is -0.94. In terms of profitability, LAB's ROE is -0.18%, compared to BEAT's ROE of -10.34%. Regarding short-term risk, LAB is less volatile compared to BEAT. This indicates lower risk in terms of short-term price fluctuations for LAB.Check BEAT's competition here
Sharps Technology Inc. Wt (NASDAQ: STSSW)
LAB vs STSSW Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, STSSW has a market cap of 839.4K. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while STSSW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas STSSW's P/E ratio is -0.03. In terms of profitability, LAB's ROE is -0.18%, compared to STSSW's ROE of N/A. Regarding short-term risk, LAB is more volatile compared to STSSW. This indicates higher risk in terms of short-term price fluctuations for LAB.Check STSSW's competition here
Span-America Medical Systems, Inc. (NASDAQ: SPAN)
LAB vs SPAN Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, SPAN has a market cap of 0. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while SPAN trades at $29.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas SPAN's P/E ratio is N/A. In terms of profitability, LAB's ROE is -0.18%, compared to SPAN's ROE of +0.17%. Regarding short-term risk, LAB is less volatile compared to SPAN. This indicates lower risk in terms of short-term price fluctuations for LAB.Check SPAN's competition here
Exactech, Inc. (NASDAQ: EXAC)
LAB vs EXAC Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, EXAC has a market cap of 0. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while EXAC trades at $49.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas EXAC's P/E ratio is 3510.33. In terms of profitability, LAB's ROE is -0.18%, compared to EXAC's ROE of +0.00%. Regarding short-term risk, LAB is more volatile compared to EXAC. This indicates higher risk in terms of short-term price fluctuations for LAB.Check EXAC's competition here
Advisory Board Co. (The) (NASDAQ: ABCO)
LAB vs ABCO Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, ABCO has a market cap of 0. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while ABCO trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas ABCO's P/E ratio is 0.52. In terms of profitability, LAB's ROE is -0.18%, compared to ABCO's ROE of +0.19%. Regarding short-term risk, LAB is more volatile compared to ABCO. This indicates higher risk in terms of short-term price fluctuations for LAB.Check ABCO's competition here
Surgical Care Affiliates, Inc. (NASDAQ: SCAI)
LAB vs SCAI Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, SCAI has a market cap of 0. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while SCAI trades at $55.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas SCAI's P/E ratio is 63.45. In terms of profitability, LAB's ROE is -0.18%, compared to SCAI's ROE of +0.09%. Regarding short-term risk, LAB is more volatile compared to SCAI. This indicates higher risk in terms of short-term price fluctuations for LAB.Check SCAI's competition here
Landauer Inc. (NYSE: LDR)
LAB vs LDR Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, LDR has a market cap of 0. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while LDR trades at $67.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas LDR's P/E ratio is N/A. In terms of profitability, LAB's ROE is -0.18%, compared to LDR's ROE of +1.17%. Regarding short-term risk, LAB is more volatile compared to LDR. This indicates higher risk in terms of short-term price fluctuations for LAB.Check LDR's competition here
Mazor Robotics Ltd. (NASDAQ: MZOR)
LAB vs MZOR Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, MZOR has a market cap of 0. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while MZOR trades at $58.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas MZOR's P/E ratio is -70.18. In terms of profitability, LAB's ROE is -0.18%, compared to MZOR's ROE of -0.14%. Regarding short-term risk, LAB is more volatile compared to MZOR. This indicates higher risk in terms of short-term price fluctuations for LAB.Check MZOR's competition here
Med-Design Corp. (The) (NASDAQ: MEDC)
LAB vs MEDC Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, MEDC has a market cap of 0. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while MEDC trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas MEDC's P/E ratio is N/A. In terms of profitability, LAB's ROE is -0.18%, compared to MEDC's ROE of N/A. Regarding short-term risk, LAB is less volatile compared to MEDC. This indicates lower risk in terms of short-term price fluctuations for LAB.Check MEDC's competition here
St. Jude Medical, Inc. (NYSE: STJ)
LAB vs STJ Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, STJ has a market cap of 0. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while STJ trades at $80.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas STJ's P/E ratio is 34.69. In terms of profitability, LAB's ROE is -0.18%, compared to STJ's ROE of +0.21%. Regarding short-term risk, LAB is more volatile compared to STJ. This indicates higher risk in terms of short-term price fluctuations for LAB.Check STJ's competition here
LifePoint Health, Inc. (NASDAQ: LPNT)
LAB vs LPNT Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, LPNT has a market cap of 0. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while LPNT trades at $64.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas LPNT's P/E ratio is 67.44. In terms of profitability, LAB's ROE is -0.18%, compared to LPNT's ROE of +0.05%. Regarding short-term risk, LAB is more volatile compared to LPNT. This indicates higher risk in terms of short-term price fluctuations for LAB.Check LPNT's competition here
Cynosure, Inc. (NASDAQ: CYNO)
LAB vs CYNO Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, CYNO has a market cap of 0. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while CYNO trades at $66.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas CYNO's P/E ratio is 105.35. In terms of profitability, LAB's ROE is -0.18%, compared to CYNO's ROE of +0.03%. Regarding short-term risk, LAB is more volatile compared to CYNO. This indicates higher risk in terms of short-term price fluctuations for LAB.Check CYNO's competition here
Pharmerica Corporation (NYSE: PMC)
LAB vs PMC Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, PMC has a market cap of 0. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while PMC trades at $29.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas PMC's P/E ratio is 47.95. In terms of profitability, LAB's ROE is -0.18%, compared to PMC's ROE of +0.04%. Regarding short-term risk, LAB is more volatile compared to PMC. This indicates higher risk in terms of short-term price fluctuations for LAB.Check PMC's competition here
Abaxis, Inc. (NASDAQ: ABAX)
LAB vs ABAX Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, ABAX has a market cap of 0. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while ABAX trades at $83.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas ABAX's P/E ratio is 70.62. In terms of profitability, LAB's ROE is -0.18%, compared to ABAX's ROE of +0.10%. Regarding short-term risk, LAB is more volatile compared to ABAX. This indicates higher risk in terms of short-term price fluctuations for LAB.Check ABAX's competition here
Envision Healthcare Corporation (NYSE: EVHC)
LAB vs EVHC Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, EVHC has a market cap of 0. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while EVHC trades at $45.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas EVHC's P/E ratio is -3.20. In terms of profitability, LAB's ROE is -0.18%, compared to EVHC's ROE of +0.07%. Regarding short-term risk, LAB is more volatile compared to EVHC. This indicates higher risk in terms of short-term price fluctuations for LAB.Check EVHC's competition here
Cotiviti Holdings, Inc. (NYSE: COTV)
LAB vs COTV Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, COTV has a market cap of 0. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while COTV trades at $44.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas COTV's P/E ratio is 26.51. In terms of profitability, LAB's ROE is -0.18%, compared to COTV's ROE of +0.14%. Regarding short-term risk, LAB is more volatile compared to COTV. This indicates higher risk in terms of short-term price fluctuations for LAB.Check COTV's competition here
AmSurg Corp (NASDAQ: AMSG)
LAB vs AMSG Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, AMSG has a market cap of 0. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while AMSG trades at $67.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas AMSG's P/E ratio is N/A. In terms of profitability, LAB's ROE is -0.18%, compared to AMSG's ROE of +0.08%. Regarding short-term risk, LAB is more volatile compared to AMSG. This indicates higher risk in terms of short-term price fluctuations for LAB.Check AMSG's competition here
Spectranetics Corp. (The) (NASDAQ: SPNC)
LAB vs SPNC Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, SPNC has a market cap of 0. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while SPNC trades at $38.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas SPNC's P/E ratio is -24.03. In terms of profitability, LAB's ROE is -0.18%, compared to SPNC's ROE of -0.61%. Regarding short-term risk, LAB is more volatile compared to SPNC. This indicates higher risk in terms of short-term price fluctuations for LAB.Check SPNC's competition here
Derma Sciences, Inc. (NASDAQ: DSCI)
LAB vs DSCI Comparison August 2026
Standard BioTools Inc. (NASDAQ: LAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LAB stands at 313.2M. In comparison, DSCI has a market cap of 0. Regarding current trading prices, LAB is priced at $0.80 on the NASDAQ, while DSCI trades at $7.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LAB currently has a P/E ratio of -11.43, whereas DSCI's P/E ratio is -0.02. In terms of profitability, LAB's ROE is -0.18%, compared to DSCI's ROE of -0.00%. Regarding short-term risk, LAB is more volatile compared to DSCI. This indicates higher risk in terms of short-term price fluctuations for LAB.Check DSCI's competition here